Clinical observation of Xiaoyin capsules combined with secukinumab in the treatment of moderate to severe plaque psoriasis

GAN Quan; WANG Beibei; SU Beibei; WANG Lixia

doi:10.6039/j.issn.1001-0408.2025.19.12

您当前的位置：

首页 >

文章列表页 >

Clinical observation of Xiaoyin capsules combined with secukinumab in the treatment of moderate to severe plaque psoriasis

更新时间：2025-10-11

- Clinical observation of Xiaoyin capsules combined with secukinumab in the treatment of moderate to severe plaque psoriasis
- ZHONGGUO YAOFANG Vol. 36, Issue 19, Pages: 2428-2432(2025)
- 作者机构：
  
  新乡市中心医院皮肤科，河南新乡　453000
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2025.19.12
  CLC： R969.4;R758.63
- Received：20 May 2025，
  
  Revised：2025-09-08，
  
  Accepted：08 September 2025，
  
  Published：15 October 2025
- 稿件说明：
移动端阅览
甘泉,王贝贝,苏蓓蓓,等.消银胶囊联合司库奇尤单抗治疗中重度斑块状银屑病的临床观察[J].中国药房,2025,36(19):2428-2432.

GAN Quan,WANG Beibei,SU Beibei,et al.Clinical observation of Xiaoyin capsules combined with secukinumab in the treatment of moderate to severe plaque psoriasis[J].ZHONGGUO YAOFANG,2025,36(19):2428-2432.
甘泉,王贝贝,苏蓓蓓,等.消银胶囊联合司库奇尤单抗治疗中重度斑块状银屑病的临床观察[J].中国药房,2025,36(19):2428-2432. DOI： 10.6039/j.issn.1001-0408.2025.19.12.

GAN Quan,WANG Beibei,SU Beibei,et al.Clinical observation of Xiaoyin capsules combined with secukinumab in the treatment of moderate to severe plaque psoriasis[J].ZHONGGUO YAOFANG,2025,36(19):2428-2432. DOI： 10.6039/j.issn.1001-0408.2025.19.12.

摘要

目的

评估消银胶囊联合司库奇尤单抗治疗中重度斑块状银屑病的临床疗效及安全性。

方法

回顾性纳入2021年1月至2024年6月在新乡市中心医院皮肤科接受治疗的105例中重度斑块状银屑病患者，根据治疗方案分为常规组（

＝32）、单抗组（

＝45）和联合组（

＝28）。常规组患者采用卡泊三醇软膏+丙酸氟替卡松乳膏+阿维A胶囊的常规治疗方案；单抗组患者在常规组基础上加用司库奇尤单抗注射液；联合组患者在单抗组基础上联合口服消银胶囊。所有患者接受至少12周的治疗。比较3组患者治疗前后的银屑病面积和严重程度指数（PASI）评分、PASI评分改善率、皮肤病生活质量指数（DLQI）评分、医生整体评估（PGA）评分、患者整体评估（PtGA）评分及治疗期间的不良反应发生情况。

结果

治疗前，3组患者上述各项评分的差异均无统计学意义（

＞0.05）。治疗后，3组患者上述各项评分均较治疗前显著降低（

＜0.05）；联合组患者的总PASI评分及红斑、鳞屑、受累体表面积评分，总DLQI评分及症状感受、日常活动、社交评分，PGA和PtGA评分均显著低于其他2组（

＜0.05），且PASI 50（即PASI评分较基线下降≥50%的患者比例，以此类推）、PASI 75、PASI 90均显著高于其他2组（

＜0.05）；单抗组患者的总PASI评分及红斑、受累体表面积评分均显著低于常规组（

＜0.05），PASI 75显著高于常规组（

＜0.05）。3组患者的总不良反应发生率比较，差异无统计学意义（

＝0.637）。

结论

消银胶囊联合司库奇尤单抗可显著改善中重度斑块状银屑病患者的皮损及生活质量，短期内具有良好的耐受性，且未明显增加严重不良反应的发生风险。

Abstract

OBJECTIVE

To evaluate the clinical efficacy and safety of Xiaoyin capsules combined with secukinumab in the treatment of moderate to severe plaque psoriasis.

METHODS

A retrospective study was conducted on 105 patients with moderate to severe pl

aque psoriasis who received treatment in the Dept. of Dermatology of Xinxiang Central Hospital from January 2021 to June 2024. According to the treatment plan， they were divided into conventional group（

＝32）， monoclonal antibody group（

＝45）， and combination group（

＝28）. The conventional group was given Calcipotriol ointment+Fluticasone propionate cream+Acitretin capsules； the monoclonal antibody group was treated with secukinumab injection in addition to the treatment of the conventional group； the combination group received oral administration of Xiaoyin capsules in addition to the treatment of the monoclonal antibody group. All patients received at least 12 weeks of treatment. The psoriasis area and severity index（PASI） score， PASI improvement rate， dermatology life quality index（DLQI） score， physician’s global assessment（PGA） score， patient’s global assessment（PtGA） score before and after treatment， and the incidence of adverse reactions during treatment were compared among the three groups.

RESULTS

Before treatment， there was no statistically significant difference in the above scores among the three groups（

＞0.05）. After treatment， the scores of all three groups of patients significantly decreased compared to before treatment（

＜0.05）； the total PASI score and erythema， scales， affected body surface area score， the total DLQI score and symptom perception， daily activity， social score， the PGA and PtGA scores of the combination group were significantly lower than the other two groups（

＜0.05）； PASI 50（the proportion of patients whose PASI score decreased by ≥50% from baseline， and so on）， PASI 75， and PASI 90 were significantly higher than the other two groups（

＜0.05）； the total PASI score， erythema， and affected body surface area score of patients in the monoclonal antibody group were significantly lower than the conventional group（

＜0.05）， and P

ASI 75 was significantly higher than the conventional group（

＜0.05）. There was no statistically significant difference in the total incidence of adverse reactions among the 3 groups（

＝0.637）.

CONCLUSIONS

The combination of Xiaoyin capsules and secukinumab can significantly improve the skin lesions and quality of life in patients with moderate to severe plaque psoriasis， with good tolerability in the short term and no significant increase in the risk of serious adverse reactions.

关键词

Keywords

references

PIASERICO S ， ORLANDO G ， MESSINA F . Psoriasis and cardiometabolic diseases：shared genetic and molecular pathways [J ] . Int J Mol Sci ， 2022 ， 23 （ 16 ）： 9063 .

FELDMAN S R ， GOMEZ B ， MENG X Y ， et al . Secukinumab rapidly improves EQ-5D health status in patients with psoriasis：pooled analysis from four phase 3 trials [J ] . J Dermatolog Treat ， 2021 ， 32 （ 7 ）： 709 - 715 .

中华医学会皮肤性病学分会，中国医师协会皮肤科医师分会，中国中西医结合学会皮肤性病专业委员会，等 . 中国银屑病生物治疗专家共识：2019 [J ] . 中华皮肤科杂志， 2019 ， 52 （ 12 ）： 863 - 871 .

MCINNES I B ， BEHRENS F ， MEASE P J ， et al . Secukinumab versus adalimumab for treatment of active psoriatic arthritis（EXCEED）：a double-blind，parallel-group，randomised，active-controlled，phase 3b trial [J ] . Lancet ， 2020 ， 395 （ 10235 ）： 1496 - 1505 .

李轲，赵铮 . 透疹消疕汤联合司库奇尤单抗治疗血热型中重度寻常型银屑病的疗效及对生存质量、PASI评分的影响 [J ] . 中医研究， 2022 ， 35 （ 10 ）： 44 - 48 .

李超 . 消银胶囊联合阿维A胶囊治疗寻常型银屑病对PASI及DLQI评分的改善研究 [J ] . 中国处方药， 2023 ， 21 （ 3 ）： 110 - 113 .

KUAI L ， LUO Y ， QU K S ， et al . Transcriptomic analysis of the mechanisms for alleviating psoriatic dermatitis using Taodan granules in an imiquimod-induced psoriasis-like mouse model [J ] . Front Pharmacol ， 2021 ， 12 ： 632414 .

中华医学会皮肤性病学分会银屑病专业委员会，张学军 . 中国银屑病诊疗指南： 2023版 [J ] . 中华皮肤科杂志， 2023 ， 56 （ 7 ）： 573 - 625 .

李元文 . 中医皮肤病学 [M ] . 北京：科学出版社， 2023 ： 156 - 160 .

ARMSTRONG A W ， READ C . Pathophysiology，clinical presentation，and treatment of psoriasis：a review [J ] . JAMA ， 2020 ， 323 （ 19 ）： 1945 - 1960 .

GRIFFITHS C E M ， ARMSTRONG A W ， GUDJONSSON J E ， et al . Psoriasis [J ] . Lancet ， 2021 ， 397 （ 10281 ）： 1301 - 1315 .

LEBWOHL M . Psoriasis [J ] . Ann Intern Med ， 2018 ， 168 （ 7 ）： ITC49 - ITC64 .

鲁智勇，郑捷 . 银屑病病情严重程度的评价方法 [J ] . 诊断学理论与实践， 2009 ， 8 （ 3 ）： 360 - 362 .

HARPER E G ， GUO C S ， RIZZO H ， et al . Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo ：implications for psoriasis pathogenesis [J ] . J Invest Dermatol ， 2009 ， 129 （ 9 ）： 2175 - 2183 .

DIANI M ， ALTOMARE G ， REALI E . T cell responses in psoriasis and psoriatic arthritis [J ] . Autoimmun Rev ， 2015 ， 14 （ 4 ）： 286 - 292 .

KAUL M ， JARVIS P ， ROZENBERG I ， et al . First-in-human study demonstrating the safety and clinical efficacy of novel anti-IL-17A monoclonal antibody CJM112 in moderate to severe plaque psoriasis [J ] . J Eur Acad Dermatol Venereol ， 2021 ， 35 （ 5 ）： 1143 - 1151 .

MALAKOUTI M ， JACOB S E ， ANDERSON N J . Treatment challenges in the management of moderate-to-severe plaque psoriasis-role of secukinumab [J ] . Clin Cosmet Investig Dermatol ， 2016 ， 9 ： 347 - 355 .

LANGLEY R G ， ELEWSKI B E ， LEBWOHL M ， et al . Secukinumab in plaque psoriasis：results of two phase 3 trials [J ] . N Engl J Med ， 2014 ， 371 （ 4 ）： 326 - 338 .

李晨丹，李领娥，孟娇玉，等 . 中医治疗寻常型银屑病血热证研究进展 [J ] . 辽宁中医药大学学报， 2021 ， 23 （ 4 ）： 117 - 121 .

强燕，王瑞平，孙晓颖，等 . 银屑病血热证中药治疗用药规律及疗效分析 [J ] . 中国皮肤性病学杂志， 2020 ， 34 （ 9 ）： 1073 - 1077 .

BAKAR R S ， JAAPAR S Z S ， AZMI A F ， et al . Depression and anxiety among patients with psoriasis：a correlation with quality of life and associated factors [J ] . J Taibah Univ Med Sci ， 2021 ， 16 （ 4 ）： 491 - 496 .

MAUL J T ， MAUL L V ， DIDASKALU J A ， et al . Correlation between dermatology life quality index and psoriasis area and severity index in patients with psoriasis：a cross-sectional global healthcare study on psoriasis [J ] . Acta Derm Venereol ， 2024 ， 104 ： adv20329 .

GHEZZI G ， COSTANZO A ， BORRONI R G . Health-related quality of life in psoriasis：literature review [J ] . J Clin Med ， 2024 ， 13 （ 16 ）： 4623 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical observation of bevacizumab combined with paclitaxel and carboplatin chemotherapy in the treatment of persistent or recurrent cervical cancer

青鹏软膏治疗神经性皮炎的临床疗效观察

Related Author

JIANG Fengxi

GUI Dingqing

ZHANG Liyi

黄丹云石海兰陈悦

Related Institution

Dept. of Gynaecology and Obstetrics， Dazhou Central Hospital

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰